Search

Displaying results 9201 - 9210 of 10000 in total
  1. Drug

    BMS-986141

    go.drugbank.com/drugs/DB14942
    Investigational

    BMS-986141 is under investigation in clinical trial NCT02985632 (A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants).

  2. Drug

    PCO-371

    go.drugbank.com/drugs/DB14946
    Investigational

    PCO-371 is under investigation in clinical trial NCT02475616 (A Single Ascending Dose Study of PCO371 in Healthy Volunteers).

  3. Drug

    Seltorexant

    go.drugbank.com/drugs/DB14961
    Investigational

    Seltorexant is under investigation in clinical trial NCT03494907 (A Study to Evaluate the Effects of Single-dose Seltorexant on Electrocardiogram Intervals in Healthy Adult Participants).

  4. Drug

    Narnatumab

    go.drugbank.com/drugs/DB14964
    Investigational

    Narnatumab is under investigation in clinical trial NCT01119456 (A Study of IMC-RON8 in Advanced Solid Tumors).

  5. Drug

    Ioflupane I-123

    go.drugbank.com/drugs/DB08824
    ApprovedInvestigational

    Ioflupane (I-123) is a radiopharmaceutical used to image dopamine neurons and diagnose Parkinsonian syndromes.

  6. Drug

    Bamet-UD2

    go.drugbank.com/drugs/DB08857
    Experimental

    Bamet-UD2 is a novel bile acid-platinum derivative.

  7. Drug

    Peginesatide

    go.drugbank.com/drugs/DB08894
    ApprovedWithdrawn

    Chemically, peginesatide is designed to mimic the pharmacological activity of erythropoietin, but is not a replica of the structure itself. … Peginesatide consists of two 21-amino acid chains that are covalently bonded by a linker derived from iminodiacetic acid and β-alanine. FDA approved March 27, 2012.

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    Amperozide

    go.drugbank.com/drugs/DB08927
    Experimental

    Amperozide is a diphenylbutylpiperazine atypical antipsychotic which antagonizes 5-HT2A receptors. It inhibits dopamine release and alters the firing of dopaminergic neurons.

  9. Drug

    Luliconazole

    go.drugbank.com/drugs/DB08933
    ApprovedInvestigational

    Luliconazole is a topical antifungal agent that acts by unknown mechanisms but is postulated to involve altering the synthesis of fungi cell membranes.

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP2C19 Inhibitors
  10. Drug

    Indalpine

    go.drugbank.com/drugs/DB08953
    ApprovedWithdrawn

    Indalpine was one of the first selective serotonin reuptake inhibitors to reach the American market. It was initially marketed by Pharmuka. However, after the emergence of widespread concern regarding adverse effects caused by SSRIs, and...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inhibitors